Oncobiologics (OTLK) Expected to Announce Earnings on Friday

Oncobiologics (NASDAQ:OTLK) is expected to announce its Q1 2026 results before the market opens on Friday, February 13th. Analysts expect Oncobiologics to post earnings of ($0.17) per share and revenue of $3.1380 million for the quarter. Interested persons may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, February 12, 2026 at 4:00 PM ET.

Oncobiologics (NASDAQ:OTLK) last released its quarterly earnings results on Friday, December 19th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.01. The company had revenue of $4.65 million for the quarter, compared to analyst estimates of $5.85 million. On average, analysts expect Oncobiologics to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Oncobiologics Stock Down 2.5%

Shares of NASDAQ:OTLK opened at $0.39 on Friday. The company has a market capitalization of $28.67 million, a price-to-earnings ratio of -0.26 and a beta of 0.10. The company has a 50 day moving average of $1.24 and a two-hundred day moving average of $1.43. Oncobiologics has a 52-week low of $0.39 and a 52-week high of $3.39.

Hedge Funds Weigh In On Oncobiologics

Hedge funds have recently bought and sold shares of the company. Goldman Sachs Group Inc. grew its stake in Oncobiologics by 74.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company’s stock worth $126,000 after buying an additional 44,063 shares during the last quarter. AQR Capital Management LLC boosted its holdings in shares of Oncobiologics by 42.7% during the first quarter. AQR Capital Management LLC now owns 84,671 shares of the company’s stock valued at $103,000 after acquiring an additional 25,351 shares during the period. Finally, Russell Investments Group Ltd. grew its position in shares of Oncobiologics by 865.2% during the second quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company’s stock worth $39,000 after acquiring an additional 21,941 shares during the last quarter. 11.20% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on OTLK shares. Wall Street Zen downgraded shares of Oncobiologics from a “hold” rating to a “sell” rating in a research note on Saturday, January 3rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Oncobiologics in a research report on Monday, December 29th. Finally, Ascendiant Capital Markets lifted their target price on Oncobiologics from $8.00 to $10.00 and gave the stock a “buy” rating in a research report on Monday, December 22nd. One investment analyst has rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $5.33.

Oncobiologics Company Profile

Oncobiologics, Inc is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.

Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary.